American Century Companies Inc. Sells 2,124,050 Shares of Kenvue Inc. (NYSE:KVUE)

American Century Companies Inc. reduced its stake in shares of Kenvue Inc. (NYSE:KVUE) by 10.1% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 18,867,138 shares of the company’s stock after selling 2,124,050 shares during the period. American Century Companies Inc. owned about 0.98% of Kenvue worth $402,813,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the stock. B. Metzler seel. Sohn & Co. Holding AG purchased a new position in shares of Kenvue in the 3rd quarter worth approximately $2,586,000. PNC Financial Services Group Inc. boosted its stake in shares of Kenvue by 1.8% in the 3rd quarter. PNC Financial Services Group Inc. now owns 422,666 shares of the company’s stock worth $9,776,000 after buying an additional 7,664 shares during the last quarter. Segall Bryant & Hamill LLC purchased a new position in shares of Kenvue in the 3rd quarter worth approximately $516,000. Advisors Asset Management Inc. boosted its stake in shares of Kenvue by 8.3% in the 3rd quarter. Advisors Asset Management Inc. now owns 20,371 shares of the company’s stock worth $471,000 after buying an additional 1,559 shares during the last quarter. Finally, Landscape Capital Management L.L.C. purchased a new position in shares of Kenvue in the 3rd quarter worth approximately $611,000. 97.64% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on KVUE shares. Canaccord Genuity Group boosted their target price on Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 5th. Citigroup cut their target price on Kenvue from $25.00 to $21.00 and set a “neutral” rating on the stock in a research note on Wednesday, January 15th. UBS Group dropped their price objective on Kenvue from $23.00 to $21.00 and set a “neutral” rating on the stock in a research note on Friday, February 7th. Deutsche Bank Aktiengesellschaft downgraded Kenvue from a “buy” rating to a “hold” rating and dropped their price objective for the company from $25.00 to $24.00 in a research note on Thursday, December 12th. Finally, Piper Sandler upped their price objective on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. According to data from MarketBeat.com, Kenvue has an average rating of “Hold” and an average price target of $23.75.

Kenvue Trading Down 0.2 %

NYSE:KVUE opened at $23.34 on Friday. The company has a market cap of $44.61 billion, a P/E ratio of 44.04, a P/E/G ratio of 2.62 and a beta of 1.25. The stock’s fifty day moving average price is $22.08 and its two-hundred day moving average price is $22.43. Kenvue Inc. has a 1 year low of $17.67 and a 1 year high of $24.46. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.00 and a quick ratio of 0.69.

Kenvue (NYSE:KVUE) last posted its earnings results on Thursday, February 6th. The company reported $0.26 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.26. Kenvue had a return on equity of 20.97% and a net margin of 6.66%. As a group, analysts expect that Kenvue Inc. will post 1.14 EPS for the current year.

Kenvue Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Stockholders of record on Wednesday, February 12th were issued a $0.205 dividend. The ex-dividend date was Wednesday, February 12th. This represents a $0.82 annualized dividend and a dividend yield of 3.51%. Kenvue’s payout ratio is currently 154.72%.

Kenvue Profile

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.